The IC50 values (μmol L−1) of DHDK and CDDP against cancer cell linesa.
| Cell line | Cancer type | IC50, μmol L−1 | |
|---|---|---|---|
| DHDK | Cisplatin | ||
| SKBR3* | Breast | 1.71 ± 0.10 | 3.04 ± 0.17 |
| MDA-MB231* | Breast | 4.49 ± 046 | 12.81 ± 0.58 |
| MCF-7* | Breast | 9.09 ± 0.46 | 11.16 ± 0.60 |
| MDA-MB453* | Breast | 10.42 ± 0.92 | 15.43 ± 0.83 |
| Calu-3 | Lung | 6.65 ± 0.42 | 7.39 ± 0.25 |
| A-549* | Lung | 8.01 ± 0.44 | 3.03 ± 0.24 |
| SKMEL-28* | Skin | 9.26 ± 0.57 | 12.94 ± 0.96 |
| HT-29 | Colon | 4.79 ± 0.54 | 4.71 ± 0.17 |
| DU-145* | Prostate | 4.62 ± 0.22 | 2.82 ± 0.14 |
| A375* | Melanoma | 6.64 ± 0.40 | 5.28 ± 0.18 |
| SKOV3* | Ovary | 9.59 ± 0.44 | 4.15 ± 0.30 |
| N87* | Stomach | 10.81 ± 0.50 | 8.35 ± 0.30 |
a
IC50: half maximal inhibitory concentration; * significant difference compared to corresponding cisplatin group p < 0.05.